Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right af­ter jump­ing on Michael Milken’s Faster­Cures board on Mon­day, the new­ly de­part­ed FDA com­mis­sion­er is back to­day with news about an­oth­er life sci­ences board post that gives him a ring­side chair to cheer on a lead play­er in the re­al-world ev­i­dence move­ment — one with very close ties to the FDA.

Ae­tion is re­port­ing this morn­ing that Got­tlieb is join­ing their board, a group that in­cludes Mo­hamad Makhzou­mi, a gen­er­al part­ner at New En­ter­prise As­so­ciates, where Got­tlieb re­turned af­ter step­ping out of his role at the FDA 2 years af­ter he start­ed.

Got­tlieb — one of the best con­nect­ed ex­ecs in bio­phar­ma — knows this com­pa­ny well. As head of FDA he cham­pi­oned the use of re­al-world ev­i­dence to help guide drug de­vel­op­ers and the agency in gain­ing greater ef­fi­cien­cies, which helped set up Ae­tion as a high-pro­file play­er in the game.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER